The Alpha CrossLaps ® ELISA is an enzyme-linked immunosorbent assay for the quantification of nonisomerized
fragments of C-terminal telopeptides of Type-I collagen ( ŽÂ¡À CTX-I) in human urine.
The Alpha CrossLaps ® ELISA is intended for use as an indicator of degradation of non-isomerized bone collagen and may be used as an aid in the identifi cation of skeletal metastases in patients with breast and prostate cancer.
In addition, the Alpha CrossLaps ® ELISA may be applied to humans as an aid in the diagnosis of Paget disease and the monitoring of anti-resorptive therapy in patients with Paget disease.
¡¤ Easy to perform
¡¤ Short incubation time
¡¤ High performance
¡¤ Rapid respond
¡¤ Type I collagen accounts formore than 90%of the organic matrix of bone and is synthesised primarily in bone. During renewal of the skeleton, Type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can bemeasured by the Alpha CrossLaps ® ELISA. Themeasurements of the specific degradation products of Type I collagen (Alpha CrossLaps ®) in human urine have been reported as useful assessment of bone resorption in Paget ¢â‚¬™s disease and for detection of bonemetastases in prostate and breast cancer.
|
Method |
Sandwich ELISA |
|
Format |
96-well microplate with reagents sufficient to test 40 samples in duplicate |
|
Detection Limit |
0.80 ng/mL |
|
Measuring Range |
0-1600 ng/ml |
|
Analyte |
Non-isomerized sequence (EKAHDGGR) specific for a part of the C-terminal telopeptide Ž¡À1 chain of type I collagen (CTX) |
|
Specimen |
Urine |
|
Specimen Volume |
25 ul pre-diluted (1+7) |
|
Precision CV Intraassay |
< 5% |
|
Precision CV Interassay |
< 10% |
|
Species Reactivity |
Human |
|
Shelf Life |
12 months from point of manufacture |
|
Assay Time |
Approx. 1.5 hours |
|
Hands on Time |
30 minutes |
)
References
1. Alexandersen et al. Non-Isomerized C-Telopeptide fragments are highly sensitive markers for monitoring disease activity and treatmentefficacy in Padget's disease of bone.
2. Cloos et al. Investigation of bone diseases using isomerised and racemised fragments of type I collagen. Calcif Tissue Int (2003);72:8-17.
3. Cloos et al. Breast cancer patients with bone metastases are characterised by increasing levels of nonisomerised type I collagen fragments. Breast Cancer Res (2003);5:R103-9.
4. Cloos et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Cli. Lab. (2004); 50:279-289.
5. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB: The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15: 32-8, 2006
6. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tanko LB, Byrjalsen I: Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 15: 1392-5, 2006
7. Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P.: Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1269-76.
8. Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C.:The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int. 2008 Apr 3.
9. Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD.: Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008 Mar;19(3):329-37.
10. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA.: Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int. 2008 Mar;19(3):339-48.
11. Henriksen K, Leeming DJ, Byrjalsen I, Nielsen RH, Sorensen MG, Dziegiel MH, Martin TJ, Christiansen C, Qvist P, Karsdal MA.: Osteoclasts prefer aged bone. Osteoporos Int. 2007 Jun;18(6):751-9.
12. Tank ƒÂ³ LB, Karsdal MA, Christiansen C, Leeming DJ.:Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? Cancer Metastasis Rev. 2006 Dec;25(4):659-68.
13. Peris P, Alvarez L, Vidal S, Kasper D, Leeming DJ, Monegal A, Angeles Mart ƒÂnez M, Pons F, Gua ƒÂ¡Àabens N.: Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif Tissue Int. 2006 Jul;79(1):22-6.